Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,504 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency.
Matthews RP, Cao Y, Patel M, Weissler VL, Bhattacharyya A, De Lepeleire I, Last S, Rondon JC, Vargo R, Stoch SA, Iwamoto M. Matthews RP, et al. Among authors: patel m. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093122. doi: 10.1128/aac.00931-22. Epub 2022 Nov 8. Antimicrob Agents Chemother. 2022. PMID: 36346229 Free PMC article. Clinical Trial.
A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants.
Wang X, Liu N, Wei Y, Zhang S, Li H, Yan B, Patel M, Wang H, Boundy KE, Colon-Gonzalez F, Zang Y, Zhao X. Wang X, et al. Among authors: patel m. Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01391-20. doi: 10.1128/AAC.01391-20. Print 2021 Feb 17. Antimicrob Agents Chemother. 2021. PMID: 33288637 Free PMC article.
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.
Roberts JA, Nicolau DP, Martin-Loeches I, Deryke CA, Losada MC, Du J, Patel M, Rizk ML, Paschke A, Chen LF. Roberts JA, et al. Among authors: patel m. JAC Antimicrob Resist. 2023 Mar 4;5(2):dlad011. doi: 10.1093/jacamr/dlad011. eCollection 2023 Apr. JAC Antimicrob Resist. 2023. PMID: 36880088 Free PMC article.
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW, Kaye KS, Losada MC, Du J, Tipping R, Rizk ML, Patel M, Brown ML, Young K, Kartsonis NA, Butterton JR, Paschke A, Chen LF. Titov I, et al. Among authors: patel m. Clin Infect Dis. 2021 Dec 6;73(11):e4539-e4548. doi: 10.1093/cid/ciaa803. Clin Infect Dis. 2021. PMID: 32785589 Free PMC article. Clinical Trial.
Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
Bradley JS, Makieieva N, Tøndel C, Roilides E, Kelly MS, Patel M, Vaddady P, Maniar A, Zhang Y, Paschke A, Chen LF. Bradley JS, et al. Among authors: patel m. J Clin Pharmacol. 2023 Dec;63(12):1387-1397. doi: 10.1002/jcph.2334. Epub 2023 Sep 2. J Clin Pharmacol. 2023. PMID: 37562063 Clinical Trial.
10,504 results
You have reached the last available page of results. Please see the User Guide for more information.